Community-acquired pneumonia primary prevention

Pneumonia Main Page
	Community-Acquired Pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Community-acquired pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Severity Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
Ultrasound
Other Diagnostic Studies
Treatment
Hospital Admission Decision
Medical Therapy
Primary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Community-acquired pneumonia primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Community-acquired pneumonia primary prevention
CDC on Community-acquired pneumonia primary prevention
Community-acquired pneumonia primary prevention in the news
Blogs on Community-acquired pneumonia primary prevention
Directions to Hospitals Treating Community-acquired pneumonia
Risk calculators and risk factors for Community-acquired pneumonia primary prevention

Vaccines

*Vaccine prevention of community-acquired pneumonia.*^[1]
Factor	Pneumococcal polysaccharide vaccine
▸ Route of administration	▸ Intramuscular injection
▸ Type of vaccine	▸Bacterial component (polysaccharide capsule)
▸ Recommended groups	▸All persons ≥ 65 years of age 'High-risk persons 2–64 years of age' 'Current smokers'
▸ Specific high-risk indications for vaccination	▸ Chronic cardiovascular, pulmonary, renal, or liver disease ▸Diabetes mellitus ▸Cerebrospinal fluid leaks ▸ Alcoholism ▸ Asplenia ▸ Immunocompromising conditions / medications ▸Native Americans and Alaska natives ▸Long-term care facility residents
▸ Revaccination schedule	▸ One-time revaccination after 5 years for ▸ (1) adults 65 years of age, if the first dose is received before age 65 years ▸ (2) persons with asplenia ▸ (3) immunocompromised persons

Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.^[1]

↑ ^1.0 ^1.1 Harper, SA.; Fukuda, K.; Uyeki, TM.; Cox, NJ.; Bridges, CB. (2005). "Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 54 (RR-8): 1–40. PMID 16086456. Unknown parameter |month= ignored (help)